Initial Public Offering (IPO)

The initial public offering (“IPO”) journey has never been straightforward. In addition to business-related financial metrics, evolving stakeholder expectations and heightening regulatory demands for resilient growth supported by well-articulated Environmental, Social and Governance (“ESG”) strategy and performance have indicated that ESG and climate-related corporate mandates growingly tip the scales when it comes to a company’s successful IPO and overall performance.
 
Against the backdrop that regulatory authorities and capital markets around the world are demanding transparent ESG disclosures from companies looking to go public, while IPO-ready companies align themselves with enhanced regulatory frameworks, some of them even make ESG practices front and center in their IPO roadshow phase to gain access to the pool of capital from international ESG-focused investors.
 
Click <a href="../../../../../uploads/EN_IPO_Journey_the_Importance_of_ESG_in_IPO_Process_20221107_VP_ET_SL_ET_SL_SJC_b180b1b534.pdf" target="_blank" rel="noopener">here</a> to learn more about the latest ESG disclosure requirements and ESG essential for IPO applicants.
 
<a href="../../../../../uploads/EN_IPO_Journey_the_Importance_of_ESG_in_IPO_Process_20221107_VP_ET_SL_ET_SL_SJC_b180b1b534.pdf" target="_blank" rel="noopener"><img src="../../../../../uploads/Cover_EN_5f415ec3d4.png" alt="" width="500" height="707" /></a>

IPO Journey.jpg

IPO Journey:  The Importance of ESG in IPO Process

The Stock Exchange of Hong Kong Ltd. (“HKEx” or the “Exchange”) published a consultation paper on 19 October 2022, seeking public feedback on proposals to expand Hong Kong’s existing listing regime to permit listings of Specialist Technology Companies. The consultation period will end on 18 December 2022.
 
The consultation paper proposes that Specialist Technology Companies listing applicants are required to have substantial investment from Sophisticated Independent Investors, and to disclose the pre-IPO financing details in their listing applications.
 
Click <a href="../../../../../uploads/article_EN_compressed_bf4f93c5c0.pdf" target="_blank" rel="noopener">here</a> to learn more about HKEx published Consultation Paper for Specialist Technology Companies Listing.
 
<img src="../../../../../uploads/EN_cover_90b9426b44.png" width="350" />

tobias-keller-2ecH5Lw3zSk-unsplash.jpg

HKEx published Consultation Paper for Specialist Technology Companies Listing

1612973910056.jpeg

HKEX Consultation Conclusions on The Main Board Profit Requirement and Review of Listing Rules Relating to Disciplinary Powers and Sanctions

A growing attention to the Biotech sector has been shown in the accelerating investments by Venture Capital funds and IPOs, as well as the expectation of innovative therapies amidst Covid-19. This article, therefore, provides a guide on Biotech investment analysis with highlighting the “3H” characteristics of Biotech industry—High inputs in R&amp;D, High Rewards, and High Risks, and demonstrating related valuation approaches for quantitative analysis.
 
Click <a href="../../../../../uploads/Investing_in_Biotech_-_A_Guide_to_Risk-Return_Analysis_with_Valuation_Techniquesv2_d1bdf4f384.pdf" target="_blank" rel="noopener">here</a> to read the full article.
 
<a href="../../../../../uploads/Investing_in_Biotech_-_A_Guide_to_Risk-Return_Analysis_with_Valuation_Techniquesv2_d1bdf4f384.pdf" target="_blank" rel="noopener"><img src="../../../../../uploads/cover_51fccbbb2f.jpeg" width="600" /></a>

127134377_m

Investing in Biotech - A Guide to Risk-Return Analysis with Valuation Techniques

abstract-267056_1920

technology-2836663_1920l

blue-1634110l

Highlights background.png